Biogen Inc (MIL:1BIIB)
€ 141.3 0 (0%) Market Cap: 20.87 Bil Enterprise Value: 25.62 Bil PE Ratio: 13.49 PB Ratio: 1.33 GF Score: 53/100

Biogen Inc at the Stifel 3rd Annual CNS Day Transcript

Mar 31, 2021 / 04:00PM GMT
Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst

Awesome. Thank you, everybody, who has been joining all morning and pinging me with questions and making this a fun event again this year. Really happy to have Al Sandrock on, the head of R&D from Biogen here for this panel, where we're going to talk about a lot of stuff across Biogen's late-stage pipeline and just kind of thematically across neuroscience.

I'm going to kick it off for a quick second by disappointing people, and hopefully, this will save my inbox from random aducanumab regulatory questions. And unfortunately, that just can't be the parameter of this discussion and Biogen can't really comment at this point in depth. So.

But I do think we're still going to have a great chat because there's a lot of late-stage readouts this year. There's a lot of different things we can talk about in neuron. So with that, Al, thank you again for doing this panel.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot